Michael Method
- Reproductive Medicine top 1%
- Ovarian cancer diagnosis and treatment 42
- Obstetrics and Gynecology top 2%
- Endometrial and Cervical Cancer Treatments 10
- Oncology top 5%
- HER2/EGFR in Cancer Research 8
- PARP inhibition in cancer therapy 7
- Pathology and Forensic Medicine top 10%
- Cancer Mechanisms and Therapy 6
-
- Breast Cancer Treatment Studies 9
-
- Advanced Breast Cancer Therapies 17
-
- Intraperitoneal and Appendiceal Malignancies 6
- Co-authors
- Ana OakninUrsula A. MatulonisHeidi DonovanEllen M. HartenbachJiuzhou WangMario M. LeitãoDomenica LorussoConleth G. Murphy
- Journals
- Gynecologic Oncology (16 papers)Journal of Clinical Oncology (16 papers)Annals of Oncology (5 papers)
- Partner nations
- United StatesSpainItaly
In The Last Decade
Michael Method
71 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 98
- Reproductive Medicine 495
- Obstetrics and Gynecology 302
- Oncology 667
- Pathology and Forensic Medicine 146
- Cancer Research 121
Countries citing papers authored by Michael Method
This map shows the geographic impact of Michael Method's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Method with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Method more than expected).
Fields of papers citing papers by Michael Method
This network shows the impact of papers produced by Michael Method. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Method. The network helps show where Michael Method may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Michael Method, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 11 | |
| 2 | 2024 | 19 | |
| 3 | 2023 | 2 | |
| 4 | 2023 | 2 | |
| 5 | 2023 | 4 | |
| 6 | Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Studybreakdown → | 2023 | 220 |
| 7 | 2023 | 1 | |
| 8 | 2023 | 5 | |
| 9 | 2023 | 1 | |
| 10 | 2022 | 1 | |
| 11 | 2022 | 30 | |
| 12 | 2022 | 5 | |
| 13 | 2020 | 1 | |
| 14 | 2020 | 1 | |
| 15 | 2020 | 36 | |
| 16 | 2014 | 40 | |
| 17 | 2012 | 137 | |
| 18 | 2012 | 4 | |
| 19 | 2008 | 46 | |
| 20 | 2008 | 2 |
About Michael Method
Michael Method is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 73 papers that have together received 1.3k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (42 papers), Advanced Breast Cancer Therapies (17 papers), Endometrial and Cervical Cancer Treatments (10 papers), Breast Cancer Treatment Studies (9 papers), HER2/EGFR in Cancer Research (8 papers), PARP inhibition in cancer therapy (7 papers), Cancer Mechanisms and Therapy (6 papers) and Intraperitoneal and Appendiceal Malignancies (6 papers). The work is most often cited by research in Reproductive Medicine (495 citations), Obstetrics and Gynecology (302 citations), Oncology (667 citations), Pathology and Forensic Medicine (146 citations) and Cancer Research (121 citations). Michael Method has collaborated with scholars based in United States, Spain and Italy. Frequent co-authors include Ana Oaknin, Ursula A. Matulonis, Heidi Donovan, Ellen M. Hartenbach, Jiuzhou Wang, Mario M. Leitão, Domenica Lorusso, Conleth G. Murphy, Toon Van Gorp and Jason Konner. Their work appears in journals such as Gynecologic Oncology, Journal of Clinical Oncology, Annals of Oncology, International Journal of Gynecological Cancer and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.